Anal Cancer and Its Screening
Authors:
F. Rob 1; J. Němcová 2,3,4; J. Šmahelová 5; J. Marx 6; O. Ondič 2,3,4
Authors‘ workplace:
Dermatovenerologická klinika 2. LF UK a Fakultní nemocnice Bulovka, Praha, pověřený přednosta MUDr. Filip Rob, Ph. D.
1; Biomedicínské centrum Lékařské fakulty v Plzni, Plzeň, prof. MUDr. Milan Štengl, Ph. D.
2; Šiklův patologický ústav, Fakultní nemocnice v Plzni, Plzeň, prof. MUDr. Michal Michal
3; Bioptická laboratoř s. r. o., Plzeň, prof. MUDr. Alena Skálová, CSc.
4; Národní referenční laboratoř pro papillomaviry a polyomaviry, Ústav hematologie a krevní transfuze, Praha, prof. MUDr. Petr Cetkovský, Ph. D., MBA
5; Chirurgická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha, doc. MUDr. Jan Fanta, DrSc.
6
Published in:
Čes-slov Derm, 97, 2022, No. 1, p. 3-15
Category:
Reviews (Continuing Medical Education)
Overview
Anal cancer is a tumour with a low prevalence but high morbidity. Due to the rarity of this tumour, therefore, its screening has not been considered until recently. However, in recent decades there has been an increase in the number of cases, especially in the population of HIV-positive men having sex with men. Since the most cases of anal cancer are squamous cell carcinomas associated with human papillomavirus (HPV) infection, as in the case of cervical cancer, there is the possibility of secondary prevention through appropriate screening. The basis of current screening examinations are digital anorectal examination, cytological examination and anoscopy. Early detection of treatable forms is important, also based on the fact that due to cultural changes and the prevalence of risk factors, an increase in the incidence of this tumour can be expected. However, education and motivation of at-risk groups of patients are necessary to increase the effectiveness of the screening, mainly by raising awareness of anal cancer and the role of risky sexual behavior and HPV infection.
Keywords:
cytology – HPV – screening – HIV – anal cancer – MSM – anoscopy
Sources
1. ALAM, N. N., WHITE, D. A., NARANG, S. K. et al. Systematic review of guidelines for the assessment and management of high‐grade anal intraepithelial neoplasia (AIN II/III). Colorectal Dis, 2016, 18, p. 135–146.
2. ALBRIGHT, J. B., BONATTI, H., STAUFFER, J. et al. Colorectal and anal neoplasms following liver transplantation. Colorectal Dis, 2010, 12, p. 657–666.
3. ALBUQUERQUE, A., NATHAN, M., CAPPELLO, C. et al. Anal cancer and precancerous lesions: a call for improvement. Lancet Gastroenterol Hepatol, 2021, 6, p. 327–334.
4. BERTISCH, B., FRANCESCHI, S., LISE, M. Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol, 2013, 178, p. 877–884.
5. BETACOURT, E. M., WAHBAH, M. M., BEEN, L. C. et al. Anal cytology as a predictor of anal intraepithelial neoplasia in HIV-positive men and women. Diagn Cytopathol, 2013, 41, p. 697–702.
6. BJEKIC, M., SIPETIC-GRUJICIC, S., DUNIC, I. et al. Human papillomavirus and anal carcinoma knowledge in men who have sex with men in Belgrade, Serbia. Int J Dermatol, 2016, 55, p. 1082–1087.
7. BLASER, N., BERTISCH, B., KOUYOS, R. D. et al. Impact of screening and antiretroviral therapy on anal cancer incidence in HIV-positive MSM. Aids, 2017, 31, p. 1859–1866.
8. BROGDEN, D. R., WALSH, U., PELLINO, G. et al. Evaluating the efficacy of treatment options for anal intraepithelial neoplasia: a systematic review. Int J Colorect Dis, 2021, 36, p. 213–226.
9. BROWN, S. R., SKINNER, P., TIDY, J. et al. Outcome after surgical resection for high-grade anal intraepithelial neoplasia (Bowen’s disease). Br J Surg, 1999, 86, p. 1063–1066.
10. BURGOS, J., CURRAN, A., LANDOLFI, S. et al. The effectiveness of electrocautery ablation for the treatment of high-grade anal intraepithelial neoplasia in HIV-infected men who have sex with men. HIV Med, 2016, 17, p. 524–531.
11. CLARKE, M. A., WENTZENSEN, N. Strategies for screening and early detection of anal cancers: A narrative and systematic review and meta-analysis of cytology, HPV testing, and other biomarkers. Cancer Cytopathol, 2018, 126, p. 447–460.
12. CLIFFORD, G. M., GEORGES, D., SHIELS, M. S. et al. A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. Int J Cancer, 2021, 148, p. 38–47.
13. COLÓN-LOPÉZ, V., SHIELS, M. S., MACHIN, M. et al. Anal cancer risk among people with HIV infection in the United States. J Clin Oncol, 2018, 36, p. 68.
14. CRANSTON, R. D., BAKER, J. R., LIU, Y. et al. Topical application of trichloroacetic acid is efficacious for the treatment of internal anal high-grade squamous intraepithelial lesions in HIV-positive men. Sex Transm Dis, 2014, 41, p. 420–426.
15. CRANSTON, R. D., HIRSCHOWITZ, S. L., CORTINA, G. et al. A retrospective clinical study of the treatment of high-grade anal dysplasia by infrared coagulation in a population of HIV-positive men who have sex with men. Int J STD AIDS, 2008, 19, p. 118–120.
16. DALING, J. R., MADELEINE, M. M., JOHNSON, L. G. et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer, 2014, 101, p. 270–280.
17. DALLA PRIA, A., ALFA-WALI, M., FOX, P. et al. High-resolution anoscopy screening of HIV-positive MSM: longitudinal results from a pilot study. Aids, 2014, 28, p. 861–867.
18. DE STROOPER, L. M. A., VERHOEF, V. M. J., BERKHOF, J. et al. Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brushbased self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecol Oncol, 2016, 141, p. 341–347.
19. DONA, M. G., BENEVOLO, M., LATINI, A. et al. Anal cytological lesions and HPV infection in individuals at increased risk for anal cancer. Cancer Cytopathol, 2018, 126, p. 461–470.
20. Epidemiologie zhoubných nádorů v České republice (online) (18.9.2021). Dostupné na www: https:// www.svod.cz/.
21. FOX, P. A., NATHAN, M., FRANCIS, N. et al. A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal highgrade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. Aids, 2006, 24, p. 2331–2335.
22. GIULIANO, A. R., LEE, J. H., FULP, W. et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet, 2011, 377, p. 932–940.
23. GOLDSTONE, R. N., HASAN, S. R., DRURY, S. et al. A trial of radiofrequency ablation for anal intraepithelial neoplasia. Int J Color Dis, 2017, 32, p. 357–365.
24. GOLDSTONE, S., PALEFSKY, J. M., GIULIANO, A. R. et al. Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis, 2011, 203, p. 66–74.
25. GRAVITT, P. E. The known unknowns of HPV natural history. J Clin Invest, 2011, 121, p. 4593–4599.
26. HERNANDEZ, B. Y., MCDUFFIE, K., ZHU, X. et al. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidem Biomarkers Prev, 2005, 14, p. 2550–2556.
27. HOOTS, B. E., PALEFSKY, J. M., PIMENTA, J. M. et al. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer, 2009, 124, p. 2375–2383.
28. KRZOWSKA-FIRYCH, J., LUCAS, G., LUCAS, C. et al. An overview of Human Papillomavirus (HPV) as an etiological factor of the anal cancer. J Infect Pub Health, 2019, 12, p. 1-6.
29. LAM, J. M. C., HOCH, J. S., TINMOUTH, J. et al. Costeffectiveness of screening for anal precancers in HIV-positive men. Aids, 2011, 25, p. 635–642.
30. LAMMÉ, J., PATTARATORNKOSOHN, T., MERCADO- ABADIE, J. et al. Concurrent anal human papillomavirus and abnormal anal cytology in women with known cervical dysplasia. Obstet Gynecol, 2014, 124, p. 242–248.
31. LANDSTRA, J. M. B., CIARROCHI, J., DEANE, F. P. Psychosocial aspects of anal cancer screening: a review and recommendations. Sex health, 2012, 9, p. 620–627.
32. LEEDS, I. L., FANG, S. H. Anal cancer and intraepithelial neoplasia screening: a review. World J Gastrointest Surg, 2016, 39, p. 41.
33. LEWIS, G. D., HAQUE, W., BUTLER, E. B. et al. Survival outcomes and patterns of management for anal adenocarcinoma. Ann Surg Oncol, 2019, 26, p. 1351–1357.
34. LORINCZ, A. T., BRENTNALL, A. R., SCIBIOR-BENTKOWSKA, D. et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer, 2016, 138, p. 2745–2751.
35. LORINCZ, A. T., NATHAN, M., REUTER, C. et al. Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions. Oncotarget, 2017, 8, p. 50510–50520.
36. MAGLENNON, G. A., MCINTOSH, P., DOORBAR, J. Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology, 2011, 414, p. 153–163.
37. MARFING, T. E., ABEL, M. E., GALLAGHER, D. M. Perianal Bowen‘s disease and associated malignancies. Results of a survey. Dis Colon Rectum, 1987, 30, p. 782–785.
38. MARKS, D. K., GOLDSTONE, S. E. Electrocautery ablation of highgrade anal squamous intraepithelial lesions in HIV-negative and HIV-positive men who have sex with men. J Acquir Immune Defic Syndr, 2012, 59, p. 259–265.
39. MONNIER-BENOIT, S., MAUNY, F., RIETHMULLER, D. et al. Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. Gynecologic Oncol, 2006, 102, p. 22–31.
40. NELSON, R. A., LEVINE, A. M., BERNSTEIN, L. et al. Changing patterns of anal canal carcinoma in the United States. J Clin Oncol, 2013, 31, p. 1569–1575.
41. NEMCOVA, J., CERNA, K., ROB, F. et al. Prevalence of high-risk human papillomavirus DNA and mRNA and its association with abnormal anal cytology in the Czech male anal cancer screening cohort. Diagn Cytopathol, 2021, 49, p. 1188–1195.
42. NIELSEN, O. V., JENSEN, S. L. Basal cell carcinoma of the anus – a clinical study of 34 cases. J Br Surg, 1981, 68, p. 856–857.
43. NIGRO, N. D., VAITKEVICIUS, V. K., CONSIDINE, B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum, 1974, 17, p. 354–356.
44. NYITRAY, A. G., NIELSON, C. M., HARRIS, R. B. et al. Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. J Infect Dis, 2008, 197, p. 1676–1684.
45. NYITRAY, A. G., D SOUZA, G., STIER, E. A. et al. The utility of digital anal rectal examinations in a public health screening program for anal cancer. J Low Genit Tract Dis, 2020, 24, p. 192.
46. PALEFSKY, J. M., BERRY, J. M., JAY, N. et al. A trial of SGN-00101 (HspE7) to treat highgrade anal intraepithelial neoplasia in HIV-positive individuals. Aids, 2006, 20, p. 1151–1155.
47. PATEL, H. S., SILVER, A. R., NORTHOVER, J. M. Anal cancer in renal transplant patients. Int J Colorect Dis, 2007, 22, p. 1–5.
48. PHILLIPS, D. H., HEWER, A., SCHOLEFIELD, J. H. et al. Smoking-related DNA adducts in anal epithelium. Mutat Res, 2004, 560, p. 167–172.
49. RAO, S., GUREN, M. G., KHAN, K. et al. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2021, 32, p. 1087–1100.
50. RICHEL, O., PRINS, J. M., DE VRIES, H. J. Screening for anal cancer precursors: what is the learning curve for high-resolution anoscopy? Aids, 2014, 28, p. 1376–1377.
51. ROBERTS, J. R., SIEKAS, L. L., KAZ, A. M. Anal intraepithelial neoplasia: A review of diagnosis and management. World J Gastrointest Oncol, 2007, 9, p. 50.
52. RICHEL, O., WIELAND, U., DE VRIES, H. J. et al. Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men. Br J Dermatol, 2010, 163, p. 1301–1307.
53. SAARILAHTI, K., ARPONEN, P., VAALAVIRTA, L. et al. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiotherapy and Oncology, 2008, 87, p. 383–390.
54. SALATI, S. A., AL KADI, A. Anal cancer–a review. Int J Health Sci, 2012, 6, p. 206.
55. SCHOLEFIELD, J. H., CASTLE, M. T., WATSON, N. F. S. Malignant transformation of high-grade anal intraepithelial neoplasia. J Br Surg, 2005, 92, p. 1133–1136.
56. SENDAGORTA, E., BeERNARDINO, J. I., ALVAREZ- GALLEGO, M. et al. Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial. Aids, 2016, 30, p. 75–82.
57. SIMARD, E. P., WATSON, M., SARAIYA, M. et al. Trends in the occurrence of high-grade anal intraepithelial neoplasia in San Francisco: 2000–2009. Cancer, 2013, 119, p. 3539–3545.
58. SINGER, M., MUTCH, M. G. Anal melanoma. Clin Colon Rectal Surg, 2006, 19, p.78–87.
59. SJODAHL, R. I., MYRELID, P., SODERHOLM, J. D. Anal and rectal cancer in Crohn‘s disease. Colorect Dis, 2003, 5, p. 490–495.
60. SNYDER, S. M., SIEKAS, L., ABOULAFIA, D. M. Initial experience with topical fluorouracil for treatment of HIV-associated anal intraepithelial neoplasia. J Int Assoc Phys AIDS Care, 2011, 10, p. 83–88.
61. SOLOMON, D., DAVEY, D., KURMAN, R. et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA, 2002, 287, p. 2114–2119.
62. STIER, E. A., CHIAO, E. Y. Anal cancer and anal cancer precursors in women with a history of HPV-related dysplasia and cancer. Semin Colon Rect Surger, 2017, 28, p. 97–101.
63. SWEDISH, K. A., FACTOR, S. H., GOLDSTONE, S. E. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis, 2012, 54, p. 891–898.
64. TINMOUTH, J., RABOUD, J., ALI, M. et al. The psychological impact of being screened for anal cancer in HIV-infected men who have sex with men. Dis Colon Rect, 2011, 54, p. 352–359.
65. TRUESDALE, M. D., GOLDSTONE, S. E. The fear factor: drivers and barriers to follow-up screening for human papillomavirus-related anal cancer in men who have sex with men. Int J STD & AIDS, 2010, 21, p. 482–488.
66. URONIS, H. E., BENDELL, J. C. Anal cancer: an overview. Oncologist, 2007, 12, p. 524–534.
67. VAN DER SNOEK, E. M., DEN HOLLANDER, J. C., AANS, J. B. et al. Photodynamic therapy with systemic meta-tetrahydroxyphenylchlorin in the treatment of anal intraepithelial neoplasia, grade 3. Lasers Surg Med, 2012, 44, p. 637–644.
68. VAN DER ZEE, R. P., RICHEL, O., VAN NOESEL, C. J. M. et al. Host Cell Deoxyribonucleic Acid Methylation Markers for the Detection of High-grade Anal Intraepithelial Neoplasia and Anal Cancer. Clin Infect Dis, 2019, 68, p. 1110–1117.
69. WEIS, S. E., VECINO, I., POGODA, J. M. et al. Prevalence of anal intraepithelial neoplasia defined by anal cytology screening and high-resolution anoscopy in a primary care population of HIVinfected men and women. Dis Colon Rectum, 2011, 54, p. 433–441.
70. WELBOURN, H., DUTHIE, G., POWELL, J. et al. Can photodynamic therapy be the preferred treatment option for anal intraepithelial neoplasia? Initial results of a pilot study. Photodiagn Photodyn Ther, 2014, 11, p. 20–21.
71. WILKIN, T. J., CHEN, H., CESPEDES, M. S. et al. A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis, 2018, 67, p. 1339– 1346.
72. WILLEMS, N., LIBOIS, A., NKUIZE, M. et al. Treatment of anal dysplasia in HIV-positive men who have sex with men in a large AIDS reference centre. Acta Clin Belg, 2017, 72, p. 29–35.
73. ZÁKOUCKÁ, H. Sexuálně přenosné infekce – moderní přístup k diagnostice – část I. Dermatol. Praxi, 2020, 14(1), p. 10–16.
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2022 Issue 1
Most read in this issue
- Discoid Lupus Erythematosus of Eyelids. Case Report
- Anal Cancer and Its Screening
- Síťovitá makula
- Linear Hyperpigmentation of the Left Pectoral Area and Linea Alba – Lichen Striatus. Minireview